Avila-Pedretti et al. presented a study carried out in 348 Caucasian patients (from Spain) diagnosed with RA and treated with adalimumab (ADA), in which individuals carrying the FCGR2A rs1801274-GG genotype did not respond to ADA treatment after 12 weeks of treatment (GG vs. AG/AA; p = 0.022; OR = 2.54; 95% CI = 1.19–5.40) [46]. Here, FCGR2A is linked to rheumatoid arthritis.